Open experience with a new myorelaxant agent for low back pain
Authors:
- 4 October 2008
- journal article
- clinical trial
- Published by Springer Nature in Advances in Therapy
- Vol. 25 (10) , 1010-1018
Abstract
Eperisone hydrochloride has been recently proposed as a muscle relaxant for the treatment of muscle contracture and chronic low back pain (LBP) as it is devoid of clinically relevant sedative effects on the central nervous system (CNS). We tested this hypothesis by performing a study of patients with LBP and muscle contracture who were treated with full-dose eperisone.Keywords
This publication has 27 references indexed in Scilit:
- Silperisone: A Centrally Acting Muscle RelaxantCNS Drug Reviews, 2006
- Tolperisone-Type Drugs Inhibit Spinal Reflexes via Blockade of Voltage-Gated Sodium and Calcium ChannelsThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Efficacy and safety of oxymorphone extended release in chronic low back pain: Results of a randomized, double-blind, placebo- and active-controlled phase III studyThe Journal of Pain, 2005
- Risk of cardiovascular events and rofecoxib: cumulative meta-analysisThe Lancet, 2004
- Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugsThe American Journal of Medicine, 2001
- Vascular Backache and Consideration of Its PathomechanismsJournal of Spinal Disorders, 1999
- Long-Lasting Muscle Relaxant Activity of Eperisone Hydrochloride after Percutaneous Administration in RatsThe Japanese Journal of Pharmacology, 1997
- Muscle cramps in chronic liver diseases and treatment with antispastic agent (eperisone hydrochloride)Digestive Diseases and Sciences, 1992
- Nonsteroidal Anti-inflammatory Drug Toxicity: Increased Risk in the ElderlyScandinavian Journal of Rheumatology, 1991
- Evaluating the efficacy of a combination therapyStatistics in Medicine, 1987